Fulgent Genetics (NASDAQ:FLGT) COO Sells $23,752.63 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 1,193 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $19.91, for a total transaction of $23,752.63. Following the completion of the transaction, the chief operating officer directly owned 362,051 shares of the company’s stock, valued at approximately $7,208,435.41. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jian Xie also recently made the following trade(s):

• On Tuesday, June 2nd, Jian Xie sold 2,146 shares of Fulgent Genetics stock. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94.

Fulgent Genetics Stock Performance

Shares of FLGT stock opened at $19.61 on Monday. Fulgent Genetics, Inc. has a 52-week low of $13.46 and a 52-week high of $31.04. The company has a market capitalization of $539.47 million, a PE ratio of -6.95 and a beta of 0.91. The business’s fifty day moving average is $19.63 and its 200 day moving average is $18.11.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). The business had revenue of $85.39 million for the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, sell-side analysts forecast that Fulgent Genetics, Inc. will post -3.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in FLGT. Allworth Financial LP purchased a new stake in shares of Fulgent Genetics in the 2nd quarter valued at $25,000. Farther Finance Advisors LLC raised its position in Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after purchasing an additional 548 shares during the period. Kestra Advisory Services LLC purchased a new position in Fulgent Genetics in the 4th quarter worth $35,000. Caitong International Asset Management Co. Ltd lifted its stake in Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after purchasing an additional 1,251 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in Fulgent Genetics in the second quarter worth $38,000. 48.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Piper Sandler raised their price target on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $27.50.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.